Adverse effects
| IVMP (n = 11) | Additional IVIG (n = 11) | p value | |
|---|---|---|---|
| We analysed continuous variables with the normal distribution, expressed as mean (SD), by the unpaired t test, and those with any non-normal distribution, expressed as median (first quartile, third quartile), by the Wilcoxon rank sum test. For nominal variables, we used the Fisher exact test. All statistical tests were two tailed. Heart rate and body temperature are minimum values and systolic blood pressure is the maximum value within 72 hours after the start of IVMP or additional IVIG. Bradycardia is defined as heart rate <2 percentile of the normal standard (Pediatr Cardiol 1979;1:123–52) and hypertension as systolic blood pressure >95 percentile of the normal standard (Pediatrics 1996;98:649–58.). Blood glucose level is the maximum value obtained on days 2, 4, and 7 after treatment with IVMP or additional IVIG. Shortening of activated partial thromboplastin time is defined as the minimum value on days 2, 4, and 7 <80% of the value on day 1. | |||
| Heart rate (/min) | 68 (63, 76) | 98 (76, 110) | 0.01 |
| Sinus bradycardia (%) | 82 | 18 | 0.01 |
| Body temperature (°C) | 35.4 (0.4) | 36.1 (0.5) | 0.002 |
| Hypothermia <35.0°C (%) | 9 | 0 | 1.00 |
| Systolic blood pressure (mm Hg) | 119 (8) | 113 (12) | 0.24 |
| Hypertension (%) | 91 | 55 | 0.15 |
| Blood glucose (mmol/l) | 7.0 (1.4) | 5.4 (0.6) | 0.007 |
| Hyperglycaemia ⩾7.0 mmol/l (%) | 55 | 0 | 0.01 |
| Shortening of activated partial thromboplastin time (%) | 27 | 18 | 1.00 |
| Embolism (%) | 0 | 0 | |
| Stool blood (%) | 0 | 0 | |